Tumor-induced Osteomalacia Disease Monitoring Program
Active, not recruiting · NCT04783428
Conditions: Tumor-induced Osteomalacia (TIO)
At a glance
- Research payments reported, 2025
- $286,504
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 23
About the trial
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Tested
- No intervention (other)
- Dates
- Started 2022-01-31; completion 2032-02-28
- Results posted
- Not yet
The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ultragenyx Pharmaceutical Inc. reported $286,504 in research payments for this study in 2025 (43 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Thomas O. Carpenter, MD Pediatric Endocrinology · New Haven, CT
- Erik A. Imel, MD Pediatric Endocrinology · Indianapolis, IN
- Janet L. Crane, M.D. Pediatrics · Baltimore, MD
- Kathryn Dahir, MD Endocrinology & Diabetes · Nashville, TN
- Suzanne Jan De Beur, M.D. Endocrinology & Diabetes · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Vanderbilt University Medical Center, TN $109,344
- Yale University $71,290
- Indiana University $43,053
- University of Virginia Medical Center, VA $39,616
- Johns Hopkins University $23,201
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.